Hansa Biopharma Ab Stock Probability Of Bankruptcy
| HNSBF Stock | USD 2.93 0.00 0.00% |
Hansa |
Hansa Biopharma AB Company chance of financial distress Analysis
Hansa Biopharma's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Hansa Biopharma Probability Of Bankruptcy | Less than 41% |
Most of Hansa Biopharma's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hansa Biopharma AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Hansa Biopharma probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Hansa Biopharma odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Hansa Biopharma AB financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Hansa Biopharma AB has a Probability Of Bankruptcy of 41.0%. This is 5.29% lower than that of the Healthcare sector and 25.24% lower than that of the Biotechnology industry. The probability of bankruptcy for all United States stocks is 2.94% lower than that of the firm.
Hansa Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hansa Biopharma's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Hansa Biopharma could also be used in its relative valuation, which is a method of valuing Hansa Biopharma by comparing valuation metrics of similar companies.Hansa Biopharma is currently under evaluation in probability of bankruptcy category among related companies.
Hansa Fundamentals
| Return On Equity | -0.89 | |||
| Return On Asset | -0.27 | |||
| Current Valuation | 189.89 M | |||
| Shares Outstanding | 52.44 M | |||
| Shares Owned By Insiders | 7.37 % | |||
| Shares Owned By Institutions | 41.33 % | |||
| Price To Earning | (46.57) X | |||
| Price To Book | 6.59 X | |||
| Price To Sales | 16.29 X | |||
| Revenue | 33.88 M | |||
| Gross Profit | 116.05 M | |||
| EBITDA | (538.83 M) | |||
| Net Income | (548.28 M) | |||
| Cash And Equivalents | 60.15 M | |||
| Cash Per Share | 1.58 X | |||
| Debt To Equity | 2.29 % | |||
| Current Ratio | 6.42 X | |||
| Book Value Per Share | 1.50 X | |||
| Cash Flow From Operations | (481.17 M) | |||
| Earnings Per Share | (0.65) X | |||
| Number Of Employees | 150 | |||
| Beta | 0.88 | |||
| Market Capitalization | 274.8 M | |||
| Total Asset | 1.01 B | |||
| Working Capital | 86 M | |||
| Current Asset | 105 M | |||
| Current Liabilities | 19 M | |||
| Net Asset | 1.01 B |
About Hansa Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hansa Biopharma AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hansa Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hansa Biopharma AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hansa Biopharma AB. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Hansa Biopharma AB information on this page should be used as a complementary analysis to other Hansa Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Complementary Tools for Hansa Pink Sheet analysis
When running Hansa Biopharma's price analysis, check to measure Hansa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hansa Biopharma is operating at the current time. Most of Hansa Biopharma's value examination focuses on studying past and present price action to predict the probability of Hansa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hansa Biopharma's price. Additionally, you may evaluate how the addition of Hansa Biopharma to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |